Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CUDC-101 是一种高效的EGFR、HDAC 和HER2抑制剂,对应的IC50值分别为 2.4、4.4 和 15.7 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 239 | 现货 | ||
2 mg | ¥ 339 | 现货 | ||
5 mg | ¥ 549 | 现货 | ||
10 mg | ¥ 721 | 现货 | ||
25 mg | ¥ 1,470 | 现货 | ||
50 mg | ¥ 2,660 | 现货 | ||
100 mg | ¥ 3,980 | 现货 | ||
200 mg | ¥ 5,680 | 现货 | ||
500 mg | ¥ 8,730 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50s of 4.4, 2.4 and 15.7 nM, respectively. |
靶点活性 | EGFR:2.4 nM, HDAC:4.4 nM, HER2:15.7 nM |
体外活性 | CUDC-101以剂量依赖的方式抑制埃罗替尼敏感的H358 NSCLC移植瘤的生长.CUDC-101也显示在埃罗替尼抗性A549NSCLC移植瘤模型中对肿瘤生长的有效抑制.CUDC-101在拉帕替尼耐药,HER2阴性,EGFR过表达MDA-MB-468乳腺癌模型和EGFR过表达CAL-27头颈部鳞状细胞癌(HNSCC)模型中显著促进肿瘤消退.每天给药120 mg/kg CUDC-101处理Hep-G2肝肿瘤模型能够诱导肿瘤的退化,比埃罗替尼所用的最大耐药剂量(25 mg/kg /天)以及vorinostat等摩尔剂量(72 mg/kg/天)时的抑制效果都更有效. |
体内活性 | CUDC-101在很多人癌细胞中表现出广谱的抗增殖活性,IC50在0.04 μM到0.80 μM之间。CUDC-101与厄洛替尼,拉帕替尼以及伏立诺他与埃罗替尼或拉帕替尼的联用相比,在大多数情况下显示出更高的效力。CUDC-101能够抑制具有拉帕替尼和埃罗替尼抗性的癌细胞系的增殖。在各种癌细胞系中,CUDC-101处理以剂量依赖性方式增加组蛋白H3和H4的乙酰化以及HDAC的非组蛋白底物如p53和α-微管蛋白的乙酰化。CUDC-101同时还能够抑制肿瘤细胞中HER3的表达,Met的扩增以及AKT再激活。 |
激酶实验 | HDAC, EGFR and HER2 inhibition assays: The activities of Class I and II HDACs are assessed using the Biomol Color de Lys system. Briefly, HeLa cell nuclear extracts are used as a source of HDACs. Different concentrations of CUDC-101 are added to HeLa cell nuclear extracts in the presence of a colorimetric artificial substrate. Developer is added at the end of the assay and enzyme activity is measured in the Wallac Victor II 1420 microplate reader at 405 nM. EGFR and HER2 kinase activity are measured using HTScan EGF receptor and HER2 kinase assay kits. Briefly, the GST-EGFR fusion protein is incubated with synthetic biotinylated peptide substrate and varying concentrations of CUDC-101 in the presence of 400 mM ATP. Phosphorylated substrate is captured with strapavidin-coated 96-well plates. The level of phosphorylation is monitored by antiphospho-tyrosine- and europium-labeled secondary antibodies. The enhancement solution is added at the end of the assay and enzyme activity is measured in the Wallac Victor II 1420 microplate reader at 615 nM. |
细胞实验 | Cancer cell lines are plated at 5000 to 10000 cells per well in 96-well flatbottomed plates with varying concentrations of CUDC-101. The cells are incubated with CUDC-101 for 72 hours in the presence of 0.5% of fetal bovine serum. Growth inhibition is assessed by an adenosine triphosphate (ATP) content assay using the Perkin-Elmer ATPlite kit. Apoptosis is routinely assessed by measuring the activities of Caspase-3 and -7 using Apo-ONE Homogeneous Assay Kit.(Only for Reference) |
别名 | CUDC 101, CUDC101 |
分子量 | 434.49 |
分子式 | C24H26N4O4 |
CAS No. | 1012054-59-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 16 mg/mL (36.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3015 mL | 11.5077 mL | 23.0155 mL | 57.5387 mL |
5 mM | 0.4603 mL | 2.3015 mL | 4.6031 mL | 11.5077 mL | |
10 mM | 0.2302 mL | 1.1508 mL | 2.3015 mL | 5.7539 mL | |
20 mM | 0.1151 mL | 0.5754 mL | 1.1508 mL | 2.8769 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CUDC-101 1012054-59-9 Angiogenesis Chromatin/Epigenetic DNA Damage/DNA Repair JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR HER HDAC Inhibitor CUDC 101 inhibit Epidermal growth factor receptor HER1 CUDC101 Histone deacetylases ErbB-1 inhibitor